FDA Guides Makers on Faster Weight-Loss Device Approvals
Published Date: 3/13/2026
Notice
Summary
The FDA just released new guidance to help companies get their weight-loss medical devices approved faster and safer. This affects anyone making devices that claim to help with weight loss, with clear steps on testing and proving benefits before selling. The guidance is effective now, so expect smoother reviews and smarter investments in device development.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Final Guidance for Weight-Loss Devices
On March 13, 2026, the FDA published a final guidance titled "Medical Devices with Indications Associated with Weight Loss--Premarket Considerations." The guidance gives recommendations on non-clinical testing and clinical study design to support premarket submissions for devices that claim weight loss or obesity treatment.
Specific Trial Design Clarifications Included
The final guidance explicitly discusses use of sham controls, statistical analysis using modified intent-to-treat populations, and inclusion of patient-reported outcomes as part of benefit-risk evaluation. It also references FDA's Q-Submission Program as a way to request feedback on proposed clinical study design.
Intended to Speed and Standardize Reviews
FDA states the recommendations reflect current review practices and are "intended to promote consistency and facilitate efficient review" of premarket submissions for weight-loss devices. The guidance consolidates two prior draft guidances into one final document to ease use.
No New Paperwork Collections Listed
The guidance states it contains no new collection of information under the Paperwork Reduction Act and refers to previously approved FDA collections with OMB control numbers such as 0910-0120, 0910-0231, 0910-0078, 0910-0844, 0910-0756, 0910-0485, 0910-0073, 0910-0130, and 0910-0119. Those existing approvals continue to apply.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-04917 — Agency Information Collection Activities: Request for Comments for a New Information Collection
The Federal Highway Administration wants your thoughts on a new way to collect info about training programs for highway construction workers. This helps make sure workers get the right skills for new tech and growing job demands. If you’re involved in construction or training, you can comment by May 12, 2026—no cost to you, just your ideas!
Next: 2026-04920 — Submission for OMB Review; Comment Request
The Department of Defense wants your feedback on a new form for businesses and individuals asking for military help with productions. They’re collecting info to make sure requests follow rules and support is available. You’ve got until April 13, 2026, to share your thoughts—no money changes, just a quick 45-minute form if you apply.